Selling a Hospice Business in 2026: Multiples, Named Buyers, and the Operator Playbook

If you own a hospice business in 2026, the M&A market is active and capital-deep. Addus HomeCare (NASDAQ: ADUS) is the largest US public home-care+hospice consolidator. Compassus (PE-backed) operates a multi-state hospice + palliative + home health platform. BrightSpring Health Services (NASDAQ: BTSG) operates hospice through its home health segment. VITAS Healthcare (Chemed Corp) is the largest US dedicated for-profit hospice. Amedisys (NYSE: AMED) is mid-acquisition by UnitedHealth/Optum (announced 2023, still pending through 2025). PE sponsors (Advent International, Webster Equity Partners, Bain Capital, Linden Capital) continue rolling up regional hospices.

What the asset is worth depends on three things: (1) CMS HQRP (Hospice Quality Reporting Program) scores and survey history (a clean recent CMS survey is a multiple-builder; F-tag deficiencies or condition-level findings are deal-killers), (2) census size and payer mix (90%+ Medicare is typical; length-of-stay distribution and routine-recert audit history matter), and (3) compliance posture (OIG / DOJ scrutiny on hospice fraud is high). This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

Named hospice M&A transactions (2022-2025)

The named buyer landscape

Public / strategic buyers

• VITAS Healthcare (Chemed Corp NYSE: CHE subsidiary) — ~$1.5B+ revenue, the largest US dedicated for-profit hospice.
• Amedisys (NYSE: AMED) — $2.3B+ revenue. UnitedHealth/Optum acquisition announced 2023, pending.
• Addus HomeCare (NASDAQ: ADUS) — ~$1.1B+ revenue, the largest US public home-care + hospice consolidator.
• BrightSpring Health Services (NASDAQ: BTSG) — $8.5B+ total revenue (hospice is one segment), IPO’d Jan 2024.
• Aveanna Healthcare (NASDAQ: AVAH) — $2.1B+ revenue with hospice segment.

PE-backed national platforms

• Compassus (PE-backed) — multi-state hospice + palliative + home health platform.
• AccentCare (Advent International) — home health + hospice + personal care.
• Three Oaks Hospice (PE-backed) — multi-state hospice.
• Empath Health (Florida-based, non-profit) — large regional.
• Heartland Hospice (HCR ManorCare).

PE sponsors active in this space

• Advent International (AccentCare), Webster Equity Partners, Bain Capital, Linden Capital, plus multiple healthcare-services PE funds.

What each buyer will pay for vs. what they reject

• Will pay premium for: strong CMS HQRP scores (the publicly-reported quality benchmark), clean OIG/DOJ compliance history with no open matters, multi-state licensure, average daily census growth, integrated palliative care + home health, modern EMR (Hospicelink, Suncoast, Homecare Homebase, MatrixCare), strong nurse and chaplain bench depth, documented bereavement program quality, normal Medicare length-of-stay distribution (not outlier-dependent).
• Will compress or reject: F-tag deficiencies or condition-level CMS survey findings, OIG/DOJ investigation history, length-of-stay-outlier dependency (especially routine recert issues), weak HQRP scores, owner-clinician dependence, single-state without expansion path, legacy EMR, undocumented GIP (general inpatient) billing patterns.

The operator-level KPI playbook buyers will diligence

Census and clinical metrics

• Average daily census (ADC): The primary scale metric. Track by site.
• Admission rate: Patients admitted per month.
• Median and average length of stay (LOS): Watch for outlier dependency.
• LOS distribution: Document percentage of patients in 0-7 days, 8-30 days, 31-180 days, 181-365 days, 365+ days.
• Discharge mix: Death, live discharge, transfer, recert-driven.

Payer mix

• Medicare percentage: 90%+ Medicare is typical (Medicare Hospice Benefit dominates the industry).
• Medicare Advantage hospice carve-in: Track participation in the CMS Hospice Carve-In demonstration model where applicable.
• Medicaid hospice: Limited; varies by state.
• Commercial hospice: Limited; track if present.

CMS compliance and quality

• HQRP scores: Hospice Quality Reporting Program publicly-reported quality measures. Document scores by measure.
• Hospice CAHPS scores: Hospice Consumer Assessment of Healthcare Providers and Systems patient/family survey scores.
• CMS survey history: 3-5 year survey history, documented; F-tags resolved.
• HOPE (Hospice Outcomes & Patient Evaluation) data quality.

OIG / DOJ compliance

• Open investigations: Any OIG, DOJ, MFCU, state-AG investigation must be disclosed.
• Recert documentation: 1st recert at 90 days, 2nd recert at 180 days, third+ at 60 days; documentation must support continued eligibility.
• GIP (general inpatient) billing patterns: Document GIP days per patient, GIP triggering criteria, and chart documentation.
• Routine recert audit defense: Documented internal-audit cycles.

Workforce

• RN, hospice aide, social worker, chaplain headcount and ratios.
• Hospice physician medical director.
• Bereavement program: 13-month minimum required by CMS.
• Volunteer program: 5%+ of patient care hours required by CMS.

Operating system and technology

• EMR: Hospicelink (Net Health), Suncoast (Complia Health), Homecare Homebase, MatrixCare, Axxess Hospice, ClearCare.
• Mobile clinician documentation.
• Bereavement and volunteer tracking.

Dangers and traps in hospice M&A

1. OIG / DOJ scrutiny on hospice fraud

Hospice fraud (routine recerts without medical necessity, GIP billing without supporting criteria, length-of-stay outlier dependency) is an OIG/DOJ enforcement priority. Any open investigation is a binary “walk” risk for most buyers.

2. F-tag deficiencies on CMS survey

Condition-level F-tags or recent survey deficiencies must be resolved. Buyer-side diligence will pull CMS survey history.

3. Length-of-stay outlier dependency

If your revenue depends on long-LOS patients (365+ days at routine home care rate), that is recert audit risk. Document recert chart support carefully.

4. GIP (general inpatient) billing patterns

GIP is a higher reimbursement category. Buyers will audit GIP triggering criteria and chart documentation; over-utilization is OIG/DOJ red flag.

5. Owner-clinician dependence

If the owner is the medical director or lead RN with personal patient relationships, build the clinical bench.

6. Single-state without expansion path

Multi-state platforms command premium multiples. Single-state operators with no documented expansion plan compress.

7. Aggregate cap exposure

Medicare hospice has an aggregate cap (per-patient lifetime cap). If your operation has cap issues, document and resolve.

8. Legacy EMR and documentation hygiene

Modern EMR (Hospicelink, Suncoast, Homecare Homebase, MatrixCare) supports the audit-defense documentation buyers require.

Our POV on hospice M&A in 2026

• Single-site low-census hospices ($500k-1.5M EBITDA) go 4x-6x EBITDA.
• Multi-site or single-state-density hospices ($1.5-4M EBITDA) go 5x-7x.
• Regional multi-state platforms ($4-12M EBITDA) go 6x-9x.
• Premium scale platforms ($12M+ EBITDA, multi-state, strong CMS HQRP, clean compliance, integrated palliative) reach 8x-11x+.

The right time to prepare is 12-18 months before going to market — address any open OIG/DOJ matters, document CMS HQRP performance, audit recert documentation, modernize EMR, develop clinical leadership bench, and confirm aggregate cap compliance.

Preparing your hospice business for sale: 12-18 months out

1. Get multi-year audited or reviewed financials.
2. Resolve any open OIG/DOJ matters. Disclose resolved matters with full documentation.
3. Document CMS HQRP performance and survey history.
4. Audit recert documentation. Internal-audit cycles for routine recerts and GIP billing.
5. Confirm aggregate cap compliance.
6. Modernize the EMR. Hospicelink, Suncoast, Homecare Homebase, MatrixCare.
7. Develop the clinical leadership bench. Medical director, clinical director, RN supervisors.
8. Document bereavement and volunteer program compliance.
9. Run a competitive process. VITAS (Chemed), Addus HomeCare, Compassus, BrightSpring, AccentCare (Advent), Aveanna, Three Oaks Hospice, plus PE sponsors directly (Advent International, Webster Equity, Bain Capital, Linden Capital).

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for a hospice business in 2026?

Single-site low-census hospices ($500k-1.5M EBITDA) typically sell at 4x-6x EBITDA. Multi-site or single-state-density hospices ($1.5-4M EBITDA) go 5x-7x. Regional multi-state platforms ($4-12M EBITDA) go 6x-9x. Premium scale platforms ($12M+ EBITDA, multi-state, strong CMS HQRP scores, clean OIG/DOJ compliance, integrated palliative care) reach 8x-11x+.

Who are the active buyers of hospice businesses right now?

Public/strategic: VITAS Healthcare (Chemed Corp NYSE: CHE, ~$1.5B+ revenue), Amedisys (NYSE: AMED, $2.3B+ revenue, UnitedHealth/Optum acquisition announced 2023 pending), Addus HomeCare (NASDAQ: ADUS), BrightSpring Health Services (NASDAQ: BTSG), Aveanna Healthcare (NASDAQ: AVAH). PE-backed: Compassus, AccentCare (Advent International), Three Oaks Hospice. Non-profit: Empath Health. PE sponsors: Advent International, Webster Equity Partners, Bain Capital, Linden Capital.

What hurts a hospice business’s valuation most?

Open OIG/DOJ investigations or unresolved matters, condition-level F-tag deficiencies on CMS survey, length-of-stay outlier dependency (especially 365+ day patients without strong recert documentation), GIP billing pattern issues, weak HQRP scores, owner-clinician dependence, single-state operations without expansion path, legacy EMR, and aggregate-cap exposure.

What is the Medicare Hospice Aggregate Cap and why does it matter?

The Medicare hospice aggregate cap is a per-beneficiary lifetime limit on Medicare hospice payments (FY2026 cap is set annually by CMS). Hospices with high cap utilization may face payment recoupments, and buyers will scrutinize cap exposure carefully. Cap utilization above 90% is a diligence concern.

Why is OIG/DOJ scrutiny so high in hospice?

Hospice fraud (routine recertification without medical necessity, GIP billing without supporting criteria, length-of-stay outlier dependency) has been a documented OIG/DOJ enforcement priority. Settlements in the hospice sector have been large and public. Any open investigation is a binary ‘walk’ risk for most buyers, and even resolved matters require full disclosure and documentation.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.

How long does it take to sell a hospice business?

Once you go to market with a buyer-paid advisor, a typical process runs 6-9 months from initial outreach to closing, with regulatory diligence extending the timeline. Add 12-18 months of preparation work before going to market.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. Highest-leverage pre-sale work: resolve any open OIG/DOJ matters, document CMS HQRP performance, audit recert and GIP documentation, modernize EMR, develop clinical leadership bench, and confirm aggregate cap compliance.

Related research

• How to sell a home care business
• How to sell a home health agency
• How to sell an infusion therapy business
• How to sell a DME business
• How to sell an urgent care center
• How to sell a physical therapy practice
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Private equity value creation
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch